| Field | Specification |
|---|---|
| Alternative names | Pyrvinium embonate |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C26H28N3.1/2 C23H14O6 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Pyrvinium pamoate, also known as Pyrvinium embonate, is an FDA-approved antihelmintic agent that inhibits WNT pathway signaling. It is supplied as a red to reddish brown solid (C26H28N3.1/2 C23H14O6, MW 575.70) at 99.75% purity.
Physical & Chemical Properties
| CAS Number | 3546-41-6 |
|---|---|
| Molecular Formula | C26H28N3.1/2 C23H14O6 |
| Molecular Weight | 575.70 g/mol |
| Purity | 99.75% |
| Appearance | Solid |
| Color | Red to reddish brown |
| SMILES | C[N+]1=C2C=CC(N(C)C)=CC2=CC=C1/C=C/C3=C(C)N(C4=CC=CC=C4)C(C)=C3.C[N+]5=C6C=CC(N(C)C)=CC6=CC=C5/C=C/C7=C(C)N(C8=CC=CC=C8)C(C)=C7.O=C(C9=C(O)C(CC%10=C%11C=CC=CC%11=CC(C([O-])=O)=C%10O)=C%12C=CC=CC%12=C9)[O-] |
| Signaling Pathway | Stem Cell/Wnt |
| Solubility | In Vitro: DMSO: 16.67 mg/mL (28.96 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, sealed storage, away from moisture and light. The compound is unstable in solutions, freshly prepared is recommended. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 16.67 mg/mL (28.96 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
The manufacturer notes that the compound is unstable in solution; prepare solutions fresh before use.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 1.67 mg/mL (2.90 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 1.67 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (16.7 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | 1.67 mg/mL (2.90 mM); suspension; requires sonication |
| How to prepare | Gives a suspension at 1.67 mg/mL. The suspension is suitable for oral and intraperitoneal dosing. For 1 mL of working solution: add 100 μL DMSO stock (16.7 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Data provided by the manufacturer.
In Vitro
Proliferation of luminal MCF-7, claudin-low MDA-MB-231, basal-like MDA-MB-468, and HER2-OE SkBr3 cells is inhibited dose-dependently by Pyrvinium pamoate (0-500 nM); against the MDA-MB-231 cell line, the IC50 value is 1170±105.0 nM. Self-renewal and proliferation of BCSCs are significantly inhibited by Pyrvinium pamoate, which also suppresses the BCSC population with a distinct phenotype. At the transcriptional level, average expression levels of FZD1 and FZD10, WNT1 and WNT7B, CTNNB1, MYC, and LRP5 are significantly decreased by Pyrvinium pamoate. Moreover, expression of other stemness genes, including ALDH1, CD44 and ABCG2, is also efficiently down-regulated by Pyrvinium pamoate[1]. In vitro, growth of colon cancer cells is blocked dose-dependently by Pyrvinium pamoate, with IC50 values (inhibitory concentration) that differ greatly, ranging from 0.6 to 65 μM in colon cancer cells carrying mutations in WNT signaling. Levels of messenger RNA (mRNA) and of protein for known WNT target genes such as c-MYC are decreased by Pyrvinium pamoate, which thereby led to the induction of p21[2]. Despite lacking efficacy on CK1, Pyrvinium pamoate ultimately inhibits Wnt signalling[3]. Specific toxicity on cardiac fibroblasts in ischemia is imposed by Pyrvinium pamoate (IC50=9.5 nM). Pyrvinium pamoate is cytotoxic to cardiac fibroblasts specifically under glucose- and glutamine-deficient conditions[4].
In Vivo
Pretreatment with Pyrvinium pamoate (500 nM) in the xenograft model strongly delays tumor size and tumor weight and markedly reduces tumor volume[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Cell Assay[1]
Dissolve Pyrvinium pamoate in DMSO at a concentration of 1 μM and store in aliquots at -20°C. Suspend cells (1×104) in 200 μL culture medium and seed into 96-well plates in quintuplicate overnight. Treat the cells with Pyrvinium pamoate (0-8,000 μM) at the indicated concentrations. After 3 days of incubation, add CCK8 (10 μL) to each well and incubate at 37°C for 1 h. Measure absorbance with a microplate reader at 450 nm[1].
Animal Administration[1]
Mice: House NOD/SCID mice under aseptic conditions in individually ventilated cages. For xenografting, resuspend 5×106 Pyrvinium pamoate-pretreated or untreated breast cancer cells (MDA-MB-231) in a 1:1 mixture of culture medium and Matrigel and transplant into mammary fat pads (fourth pair) of 4-6-week-old mice. After injection, measure tumor size with calipers each day and plot tumor growth. At the endpoint, sacrifice the mice and harvest the tumors. Fix all tumors in formalin and embed in paraffin for hematoxylin and eosin and immunohistochemical staining[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression. Mol Cancer 2025 Dec 18;24(1):310. PMID: 41413567
MBD3 deficiency decommissions the NuRD complex and orchestrates the epigenetic regulation of gene expression to suppress neuroblastoma progression. Neuro Oncol 2026 Jan 7:noaf297. PMID: 41499431
Pyrvinium pamoate regulates MGMT expression through suppressing the Wnt/β-catenin signaling pathway to enhance the glioblastoma sensitivity to temozolomide. Cell Death Discov 2021 Oct 12;7(1):288. PMID: 34642308
Cell Mol Neurobiol. 2026 Jan 24;46(1):36.
Upregulated ARMCX1 suppresses nasopharyngeal carcinoma progression by promoting TRIM21-mediated β-catenin degradation. Cell Oncol (Dordr) 2026 Jan 14;49(1):25. PMID: 41533266
Pyrvinium pamoate inhibits the survival of intracellular Mycobacterium tuberculosis through suppression of macrophage ferroptosis. Bioorg Chem 2026 Jul 5:175:109753. PMID: 41875752
High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia. Transl Oncol 2021 May;14(5):101048. PMID: 33667892
Exploring the impact of mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 on breast cancer cell metabolism. BMC Cancer 2024 Nov 16;24(1):1415. PMID: 39550554
Quantitative Proteomics Unveils the Synergistic Effects of Combination Drugs on Cytoskeleton Composition and Autophagy-Mediated Cell Death in Neuroblastoma. J Proteome Res 2025 Jul 4;24(7):3578-3596. PMID: 40526398
Casein kinase 1α regulates testosterone synthesis and testis development in adult mice. Endocrinology 2023 Mar 13;164(5):bqad042. PMID: 36929849
